Current Clinical Trials


    LIBERATE is a randomized controlled clinical trial comparing use of bupivacaine with the adjuncts dexamethasone and epinephrine to liposomal bupivacaine in interscalene nerve block for shoulder arthroplasty patients.

  • PULM: Pulmonary Arterial Hypertension - ARTISAN

    The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).


    Dr. Jason Gluck is participating in this trial collecting information which will provide clinicians with a better understanding of the Cordella PA Sensor System as a potential solution for proactive Heart Failure management, early detection of fluid overload and possibly the prevention of worsening Heart Failure symptoms.

  • CANCER: Genomic Profiling IMPACT (MSK 12-245)

    The purpose of this genomic profiling study is to determine whether certain genes in cancer may be abnormal.

  • CANCER: Bladder/Urothelial Cancer A031701 (GU)

    This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

  • CARDIO: Heart Failure - At Home-HF Pilot

    Dr. Radojevic and the Heart Failure Team are participating in this trial to evaluate the efficacy and safety of the Furoscix Infusor versus continued medical therapy in patients with chronic heart failure and fluid overload.

  • CARDIO: Heart Failure - DAPA TIMI 68

    Dr. Jaiswal and Hartford Hospital’s Heart Failure Department are enrolling patients in this international trial for patients with heart failure and reduced ejection fraction who will be randomized to dapagliflozin versus placebo while in the hospital.

  • CANCER: Thoracic Cancer LUNGMAP

    This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400).

  • CARDIO: Heart Failure - GUIDE-HF

    Under the direction of Dr. Haronian, the Heart Failure Team is participating in the CardioMEMs Heart Failure System which is currently the only FDA approved system for previously hospitalized NYHC III heart failure patients.

  • CANCER: Endometrial Cancer MSK 20-067

    This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

  • CARDIO: Heart Failure - ANTHEM-HFrEF Pivotal Study

    Dr. Joseph Radojevic is the Principal Investigator of the ANTHEM Trial which will try to determine whether Autonomic Regulation Therapy (ART) in addition to medical therapy is safe and more effective than medical therapy alone for the treatment of heart failure.

  • CANCER: Ovarian Cancer NRG-CC008

    This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

  • CANCER: Bladder Cancer MSK 19-374

    This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG.

  • CARDIO: HeartFailure - PARAGLIDE-HF

    Dr. Jaiswal and the Heart Failure Team will participate in this study investigating certain blood tests that may help identify patients that are at increased risk of death or re-hospitalized again after discharge. This blood test will reflect elevated pressures or stress on the heart to help identify patients at higher risk.

  • CARDIO: Electrophysiology - LEADR

    Dr. Meir Friedman is the Principal Investigator for this trial. The Next Generation ICD Lead is indicated for the treatment of subjects who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. The purpose of this study is to assess the safety and efficacy of the Next Generation ICD Lead.

  • CANCER: Thoracic Cancer S1900E

    This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

  • CANCER: Biospecimen s15-­01162

    This is a non-­interventional multicenter human research study in which we hope to better understand genetic and epigenetic changes that take place in T cells in Cutaneous T-­cell lymphoma (CTCL).

  • CARDIO: Electrophysiology - VANISH-2

    Under the direction of Eric Crespo, MD and the Electrophysiology Department, this study will determine whether catheter ablation or antiarrhythmic drug therapy provides the most effective control of important clinical outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia.

  • CARDIO: Electrophysiology - The Arm Aflutter Study

    Dr. Aneesh Tolat is the Principal Investigator for this trial evaluating the safety, feasibility, and efficacy of performing typical atrial flutter ablation through the arm.

  • CANCER: Multiple Tumor Types TAPUR

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

  • PSYCH: Neural Architecture of Social Emotional Processing and Regulation in Autism Spectrum Disorder

    This study delineates the temporal dynamics of the neural networks underlying social behaviors and emotional processing in relation to the diagnosis of autism spectrum disorder (ASD) and its social traits.

  • CARDIO: Structural - APOLLO

    Dr. Talhat Azemi in conjunction with the Structural Heart Team are participating in this international trial evaluating the safety and efficacy of the Medtronic Intrepid TMVR system in patients with moderate to severe or severe symptomatic mitral regurgitation who are unable to have standard transcatheter or surgical repair.

  • CANCER: Breast Cancer A011801

    This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer.

  • CARDIO: Structural - RESTORE

    RESTORE is a multi-center, non-randomized trial designed to evaluate the safety and effectiveness of the HARPOON Beating Heart Mitral Valve Repair System in patients with severe degenerative mitral regurgitation (DMR).

  • CANCER: Thoracic Cancer MSK 20-415

    The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.

  • CANCER: Multiple Myeloma EAA181 (EQUATE)

    Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

  • CARDIO: Structural - CORCINCH-HF

    This study is a randomized trial to evaluate the safety and effectiveness of the AccuCinch Ventricular Restoration System and compare it to standardized heart failure medication.

  • CARDIO: Vascular - SSB 11-02

    The primary objective of the study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis (TBE device) is safe and effective in treating thoracic aortic pathologies.

  • CANCER: Prostate Cancer GU009 (PREDICT-RT)

    Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation

  • CARDIO: Vascular - CREST-2

    Dr. Parth Shah and the Vascular Surgery Team will be participating in this two-parallel multi-centered, randomized, observer-blinded endpoint clinical trial. One trial will assess treatment differences between intensive medical management alone compared to carotid endarterectomy with intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting plus intensive medical management.

  • CANCER: Rectal Cancer MSK 19-288

    The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.

  • CARDIO: Vascular - CREST-H

    Dr. Shah in conjunction with the Vascular Surgical team will participate in this trial to determine whether patients with cerebral hemodynamic impairment and mild cognitive impairment benefit from carotid revascularization.

  • CANCER: Cervical Cancer GOG-3043

    This is a randomized controlled trial to compare survival for patients who underwent robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.

  • CANCER: Breast Cancer MSK 21-183

    The purpose of this study is to find out how often the researchers can avoid an ALND in women with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have only 1 or 2 affected lymph nodes, it will be possible to perform the less radical standard SLNB during surgery.

  • CARDIO: Cardiac Surgery - ON-X Post Approval Clinical Registry Study

    Dr. Robert Hagberg and the Cardiac Surgical Team will evaluate the On-X aortic valve performance in normal general open practice using a new lower anticoagulant (blood thinner) dose approved and recommended by the United States Food and Drug Administration (FDA) in 2015.

  • CARDIO: Cardiac Surgery - PERIGON

    The purpose of this trial is to evaluate the safety and effectiveness of the Medtronic Model 400 aortic valve bioprosthesis in a patient undergoing surgical aortic valve replacement of a native aortic valve, or replacement of a failed prosthesis.

  • CANCER: Leukemia SY-1425-202

    This is an open-label Phase 2 study in adult RARA-positive, previously untreated AML patients who are ineligible for standard induction therapy will consist of 3 parts.

  • CARDIO: Cardiac Surgery - Terminate AF Study

    The purpose of the clinical study is to evaluate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices to expand the Indication for use to include the treatment of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal AF) in subjects undergoing concomitant cardiac surgery.

  • CANCER: Lung Cancer - EA5182

    The primary objective of this trial is to evaluate progression-free survival (PFS) of osimertinib (AZD9291) and bevacizumab versus osimertinib (AZD9291) alone as first-line treatment for patients with metastatic EGFR-mutant lung cancers.

  • CANCER: Endometrial Cancer (GYN POEM Trial)

    The purpose of this study is to learn how cancer-related distress and/or reproductive concerns affect a woman's decision to remove or preserve her ovaries during surgery for endometrial cancer.


    This study hopes to demonstrate that use of the Sentinel Cerebral Protection System significantly reduces the risk of peri-procedural stroke <72 hours after transcatheter aortic valve replacement (TAVR).

  • CARDIO: Cardiac Catheterization - STEMI DTU

    This trial hopes to demonstrate that left ventricular unloading with Impella and a 30 minute delay to reperfusion when compared with immediate PCI will show a reduction in infarct size and heart failure related clinical events.

  • CANCER: Breast Cancer (CAMBRIA-1)

    We are doing this study to learn more about an experimental drug called camizestrant. We want to see if extended therapy with camizestrant is better at preventing disease recurrence (disease that comes back) than continuation of standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen, the drugs that you and other patients with early ER+/HER2- breast cancer are currently receiving). We also want to better understand the studied disease and associated health problems.

  • CANCER: Lung Cancer - Pragmatica

    This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent).

  • CARDIO: Cardiac Catheterization - Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa

    People who have had a heart attack can have another heart attack and stroke in the future. The test being researched is a blood test that is designed to guide personalized treatment designed to prevent those events.

  • CARDIO: Preventive Cardiology - The Horizon Study

    The Horizon Study is a randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with known cardiovascular disease.

  • CANCER: Rectal Cancer - Janus

    This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer.

  • CANCER: Lung Cancer - Modulation of Lung Immune Responses to Viral Infection

    The purpose of this study is to examine interactions between lung immune cells and environmental microbial factors to understand immunological mechanisms.

  • CARDIO: Preventive Cardiology - The CASCADE FH Registry

    CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia is being conducted under the direction of Dr. Paul Thompson and Preventive Cardiology.

  • CARDIO: Electrophysiology – Jewel IDE Study

    Dr. Zweibel and the Electrophysiology team will study the clinical evaluation of the Jewel P-WCD , a patch-wearable Cardioverter Defibrillator in patients who are at high risk for sudden cardiac arrest.

  • CANCER: Assessing Barriers to Minorities' Participation in Oncology Clinical Trials

    The aim of this study is to assess baseline health literacy, healthcare information sources, clinical trial knowledge, as well as barriers to these, in Spanish-speaking Hispanics and other minorities served by Hartford HealthCare.

  • CARDIO: Volunteers needed to Complete a Short Survey Evaluating an Exercise Prescription Tool

    Research volunteers are needed for a study conducted by Dr. Linda Pescatello, her research team from the University of Connecticut, and Dr. Gregory Panza from Hartford Hospital. We would like to gain your feedback on an exercise prescription tool that health care providers can use to prescribe exercise to their patients.

  • CANCER: Gastroesophageal Cancer - mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab

    The study's purpose is to determine if overall survival is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma.

  • CANCER: Genitourinary Cancer - GUIDANCE

    This study's aim is to identify whether or not intensifying or de-intensifying treatment for prostate cancer depending on genomic risk category will promote better health outcomes.

  • CARDIO: Preventive Cardiology (iSCAD)

    The aim of the International SCAD (iSCAD) Registry is to serve as an internationally collaborative, multicenter registry coordinated by an experienced, centralized, coordinating center in an effort to increase the pace of patient recruitment and thereby increase statistical power of studies related to SCAD. This observational iSCAD Registry is being conducted under the direction of Dr. Stephanie Saucier and Preventive Cardiology.

  • CARDIO: Vascular Surgery C2LOE

    Dr. Parth Shah and the Vascular Surgery Team will be participating in the Long-Term Observational Extension of Participants in the CREST-2 (C2LOE) Randomized Clinical Trial study. The purpose of C2LOE is to assess post-procedural efficacy of carotid endarterectomy and carotid stenting.

  • CANCER: Biospecimens (MSK 06-107)

    This protocol allows MSK to collect and keep biospecimen samples in order to conduct research in the present and maintained for future research.

  • CANCER: Pancreatic Cancer - Perioperative versus Adjuvant Chemotherapy

    This study seeks to determine whether giving chemotherapy both before and after surgery provides better patient outcomes compared to only giving chemotherapy after surgery in patients with pancreatic cancer.

  • CARDIO: Heart Failure - Integra-D

    The purpose of this study is to evaluate the device effectiveness in converting induced VF at the time of implantation.

  • CARDIO: Heart Failure - Aim Higher

    The purpose of this study is to determine whether CCM® treatment will reduce the occurrence of cardiovascular mortality and heart failure hospitalizations in patients with less severe heart failure.

  • CANCER: Lung Cancer - Early Detection of Tobacco-Associated Lung Cancer

    Lung cancer is the only tobacco-related malignancy that currently has an effective, widely recommended screening test: low dose CT (LDCT) of the chest. The purpose of this study is to evaluate how a combination of biomarkers acquired from various body fluids can perform compared to the current standard chest LDCT screening test.

  • CARDIO: Ventricular Tachycardia (RADIATE-VT Trial)

    The RADIATE-VT trial (NCT 05765175) is the first international, multi-center, randomized controlled trial to evaluate the safety and efficacy of cardiac radioablation (CRA) with Varian's CRA system compared to repeat catheter ablation for patients with high-risk refractory ventricular tachycardia (VT).

  • CANCER: Hospice - Home Hospice Experience with Telemedicine

    Integration of the oncologist in the development of the patient's end-of-life care plan and medical decision-making process ("shared care") during the transition to hospice may remove known barriers to end-of-life care and impact the patient, family and care team's experience. This study serves to assess the feasibility of implementing this shared care model in a single-center, community-based hospital system, and measure the impact of the use of telemedicine to integrate the oncologist in the hospice setting.

  • CANCER: Breast Cancer - Trial to Minimize Non-Response to Aerobic Training

    This study is designed to evaluate the cardiorespiratory fitness (CRF) response rate to different aerobic therapy (AT) doses in patients with post-treatment primary breast cancer.

  • CANCER: Post Hospital Discharge

    This study seeks to assess the feasibility of a digital remote patient monitoring program with the aim of enhancing a patient's access to timely symptom management. This can lead to benefits in patient engagement, quality of life, and hospital utilization.

  • CANCER: Cancer-Based Anxiety - Anxiety Intervention for Latino/Latina/Hispanic Older Adults and Caregivers

    The Managing Anxiety from Cancer (MAC) intervention exists to help older adults with cancer and their caregivers, and is considered part of the standard of care. The MAC intervention, though, has not been culturally tailored to the latino/a or hispanic population, which in some cases experience clinically significant untreated anxiety. This study is designed to help tailor MAC for this population.

  • CANCER: Colorectal Cancer - Microbiota Modulation of Chemotherapy-related Pain and Fatigue

    This research project was designed to better understand the persistent pain and fatigue after cancer treatment. Using a bio-omics approach, the study will be the first to longitudinally investigate the relationship among lifestyle factors and gut/plasma microbiome pattern, and to explore the dynamic changes of microbial genomes to predict pain and fatigue in CRC patients.

  • CANCER: Colorectal Cancer - Colorectal Cancer Screening Cohort Study

    This is a two part study that examines various factors that influence colorectal screening behavior, and uses a multi-arm randomized trial to test a brief text messaging intervention designed to increase individuals' likelihood of engaging in colorectal cancer screening.

  • CANCER: Gynecological Cancer - Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

    The primary objective is to examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.

  • CANCER: Liver Cancer - Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

    The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).

  • CANCER: Breast Cancer NRG-BR009

    This study seeks to determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

  • CANCER: Lung Cancer - MSK 21-465

    This study is to see whether or not intervention before progression in certain patients can produce better outcomes for these patients.

  • CANCER: Lung Cancer - KontRASt-06

    This is a non-randomized, open-label, single arm, multicenter, phase II study evaluating the antitumor activity and safety of JDQ443 single agent as first-line treatment for participants with locally advanced or metastatic KRAS G12C-mutated NSCLC. The study will have 2 non-comparative cohorts (Cohort A and B) that will recruit participants in parallel.

  • CANCER: Breast Cancer - A012103

    This study seeks to compare the effect of pembrolizumab versus observation in patients with early-stage triple-negative breast cancer who have achieved a pathologic complete response after preoperative chemotherapy + pembrolizumab.

  • CANCER: Melanoma - MSK 23-098

    The purpose of this trial is to see how well the vaccine IO102/IO103 works in people with inoperable melanoma. People in this study will get IO102/IO103 with two drugs: nivolumab and relatlimab. It is hoped that combining the vaccine with these anti-cancer medications will boost the immune system to fight cancer.

  • CANCER: Liver Cancer ML44719

    This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC) who have Child-Pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety and efficacy of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.

  • PSYCH: Children of Parents with Alzheimer's Needed for Research on Brain Structure/Function

    Children of parents with alzheimer's are needed for research on brain structure/function. To be eligible individuals must be between the ages of 40 and 60, have a mother or father diagnosed with dementia/Alzheimer's after age 60, not be currently exercising, be willing to exercise 3 times per week for 6 months at Hartford Hospital, and be willing to undergo an MRI scan.

  • PSYCH: Healthy Volunteers Needed for Neuroimaging (Brain Scan) Study

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are recruiting participants without psychiatric problems for a neuroimaging (brain scan) study. We are offering a study that involves undergoing a neuroimaging (brain) scan while also participating in tasks that will examine your brain functioning.

  • PSYCH: Participants Needed for Sickle Cell/Brain fMRI Research Study

    This research study intends to understand how pain affects the brains of people with sickle cell disease. Healthy volunteers who are African-American and between the ages of 15-30 years are eligible. One 3-hour visit will be required and you will be compensated for your time!

  • PSYCH: Researchers seeking adolescents with and without ADHD, ages 9-18

    The Olin Neuropsychiatry Research Center at The Institute of Living is conducting a study of adolescents with ADHD ages 9-18 and healthy adolescents ages 9-18 to look at how the brain functions during decision-making in cognitive tasks. The study will require at least 1 visit to complete interviews with clinical staff and MRI scans. Qualified volunteers will be compensated $20 per hour for participation.

  • PSYCH: Researchers Seeking Adults with Autism Spectrum Disorders, Ages 18-40

    The Olin Neuropsychiatry Research Center at The IOL is conducting a study of adults with autism spectrum disorders (ASD) ages 18-40 to look at how our brains process social interactions and how it is different in individuals with ASD. The study may require two or more visits to complete interviews with clinical staff, MRI scans and an EEG. Qualified volunteers are compensated $20/hour for their time.

  • PSYCH: Healthy Adults Sought For Research Study

    The Olin Neuropsychiatry Research Center at The Institute of Living is looking for healthy adults 18-60 with no significant history of mental illness. Participation will include: interviews and questionnaires, pencil and computer games, and an MRI. Qualifying persons will be compensated $20 per hour for their time. Lunch provided.

  • PSYCH: Participants with a Family History of Alcoholism Needed for Research Study

    Are you a healthy, right-handed adult between the ages of 18 and 35? You may qualify to participate in a research study at The Olin Neuropsychiatry Research Center at the IOL. Individuals matching that description who have relatives with alcoholism or a history of alcoholism are eligible to participate in this research study.

  • PSYCH: Help for Hoarding at No Cost

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is conducting a study for people with Hoarding Disorder.

  • PSYCH: Healthy Volunteers Needed for Research Study

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is recruiting participants with no current or lifetime history of psychiatric problems for a research study.